CLOs on the Move

Advent Advisory Group

www.adventadvisorygroup.com

 
Advent Advisory Group is a Astoria, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Cytomation

Cytomation is a Fort Collins, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

SouthStar Health Group

SouthStar Health Group is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Histogen

A regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. Two product families - a proprietary liquid complex of embryonic-like proteins and growth factors` and a human Extracellular Matrix (ECM) material` ExCeltrix..

Pathway Senior Living

Pathways Senior Living is a dynamic and growing senior living company based in Phoenix, Arizona. Most companies in our industry talk about how they can make their institutional facilities more "home-like." At Pathways, we think it`s a lot easier to just build a home. Our Assisted Living and Memory Care Neighborhoods offer residents the opportunity to continue to live in a comfortable family-style home while having access to the 24/7 support and care of our licensed and trained caregivers. Residents can take advantage of amenities and activities throughout the neighborhood and not be limited to one floor or wing of a larger building. We go to great lengths to avoid the typical institutional elements like lobbies and elevators, medication carts and nurses stations. We believe that by creating a more comfortable and appealing environment, our residents are able to develop stronger relationships and continue to enjoy a live of meaning and purpose.

Cardionomic

Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.